CLAIMS

1. An oral care composition comprising a sesquiterpenoid and an antimicrobial agent, wherein the sesquiterpenoid and the antimicrobial agent are present in an amount effective to inhibit and/or degrade a biofilm in the oral cavity, wherein the sesquiterpenoid ~~being~~ is present in the composition at a concentration of 0.0001 to 1 % by weight, and wherein the sesquiterpenoid is bisabolol wherein the antimicrobial agent is selected from Triclosan, cetyl pyridinium chloride, magnolia extract, magnolol, honokiol, butyl magnolol, propyl honokiol, zinc chloride, zinc lactate, zinc citrate, stannous fluoride and stannous chloride.

2. The oral care composition according to claim 1 wherein the bisabolol is present in the composition at a concentration of 0.025 to 0.075% w/w.

~~3. An oral care composition according to any preceding claim, wherein the antimicrobial agent is selected from Triclosan, cetyl pyridinium chloride, magnolia extract, magnolol, honokiol, butyl magnolol, propyl honokiol, zinc chloride, zinc lactate, zinc citrate, stannous fluoride and stannous chloride.~~

43. An oral care composition according to claim ~~3~~ 1 or claim 2 wherein the antimicrobial agent is Triclosan.

~~5~~4. An oral care composition according to any preceding claim, wherein the ~~sesquiterpenoid~~ bisabolol has a BEC_{50} in the presence of the antimicrobial agent of 25% or less compared to the BEC_{50} of the ~~sesquiterpenoid~~ bisabolol in the absence of the antimicrobial agent.

~~6~~5. An oral care composition according to claim ~~5~~4, wherein the bisabolol has a BEC_{50} of 20 ppm to 30 ppm.

~~7~~6. An oral care composition according to any preceding claim, wherein the antimicrobial agent has a BEC_{50} in the presence of sesquiterpenoid 75% or less compared to the BEC_{50} of the antimicrobial agent not in the presence of the sesquiterpenoid.

~~8~~7. An oral care composition according to claim ~~7~~6, wherein the antimicrobial agent has a BEC_{50} in the presence of sesquiterpenoid 50% or less compared to the BEC_{50} of the antimicrobial agent not in the presence of sesquiterpenoid.

~~9~~8. An oral care composition according to claim ~~6~~5, wherein the antimicrobial agent is Triclosan and the Triclosan has a BEC_{50} of from 1 ppm to 3 ppm.

~~10~~9. An oral care composition according to any preceding claim, wherein the composition comprises one or more further agents selected from an anti-plaque agent, a whitening agent, a sweetening agent, a cleaning agent and a flavouring agent.

~~11~~10. An oral care composition according to any preceding claim, wherein the composition comprises an orally acceptable carrier for a toothpaste, a dental cream, a mouthwash, a chewing gum or a denture adhesive.

~~12~~11. An oral care composition according to any preceding claim for use as a medicament.

~~13~~12. A composition comprising bisabolol and an antimicrobial agent for the treatment or prevention of a condition caused by biofilm formation, wherein the bisabolol ~~is~~ being present in the composition at a concentration of 0.0001 to 1 % by weight.

~~14~~13. A composition according to claim ~~13~~12, wherein the condition is in the oral cavity.

~~15~~14. A composition according to claim ~~14~~13, wherein the condition is selected from dental plaque, tooth decay, periodontal disease, halitosis, or gingivitis.

15. An oral care composition according to any preceding claim, wherein the antimicrobial agent is selected from cetyl pyridinium chloride, magnolia extract, magnolol, honokiol, butyl magnolol, propyl honokiol, zinc chloride, zinc lactate, zinc citrate, stannous fluoride and stannous chloride.

~~16. A method of inhibiting biofilm formation and/or degrading a biofilm in a subject comprising administering to the subject a composition comprising bisabolol and an antimicrobial agent, wherein the bisabolol is present in the composition at a concentration of 0.0001 to 1% by weight.~~

Replacement Sheet

17. A method according to claim 16, wherein the composition is applied to an oral cavity.

18. A method according to claim 17, wherein the method prevents or treats a condition caused by biofilm formation in the oral cavity.

19. A method according to claim 18, wherein the condition is selected from dental plaque, tooth decay, periodontal disease, halitosis, or gingivitis.

20. A method according to any of claims 16 to 19, wherein the biofilm is formed from a single species of bacteria.

21. A method according to any of claims 16 to 19, wherein the biofilm is formed from a plurality of species of bacteria.

22. A method according to any of claims 16 to 21, wherein the biofilm is formed from one or more bacteria selected from *A. viscosus, Lactobacillus casei, Streptococcus oralis, Fusobacterium nucleatum* and *Veillonella parvula.*

23. Use of a bisabolol in a concentration of 0.0001 to 1% by weight for enhancing the anti-biofilm activity of an antimicrobial agent.

ion: 13.06.2011 12:17:52 - 13.06.2011 12:20:37. This page 16 of 24 AMENDED SHEET 2011 12:19:55
eceived at the EPO on Jun 13, 2011 12:20:37. Page 16 of 24